摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

5,6-dihydroxy-2-{3-[4-(2-isopropoxy-phenyl)-piperazin-1-yl]-propyl}-hexahydro-isoindole-1,3-dione | 866097-11-2

中文名称
——
中文别名
——
英文名称
5,6-dihydroxy-2-{3-[4-(2-isopropoxy-phenyl)-piperazin-1-yl]-propyl}-hexahydro-isoindole-1,3-dione
英文别名
5,6-Dihydroxy-2-[3-[4-(2-propan-2-yloxyphenyl)piperazin-1-yl]propyl]-3a,4,5,6,7,7a-hexahydroisoindole-1,3-dione
5,6-dihydroxy-2-{3-[4-(2-isopropoxy-phenyl)-piperazin-1-yl]-propyl}-hexahydro-isoindole-1,3-dione化学式
CAS
866097-11-2
化学式
C24H35N3O5
mdl
——
分子量
445.559
InChiKey
REDXKWFDLIKODE-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.2
  • 重原子数:
    32
  • 可旋转键数:
    7
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.67
  • 拓扑面积:
    93.6
  • 氢给体数:
    2
  • 氢受体数:
    7

反应信息

点击查看最新优质反应信息

文献信息

  • [EN] ALPHA, OMEGA-DICARBOXIMIDE DERIVATIVES AS USEFUL URO-SELECTIVE Alpha1Alpha ADRENOCEPTOR BLOCKERS<br/>[FR] DERIVES D'ALPHA, OMEGA-DICARBOXIMIDE UTILES EN TANT QU'INHIBITEURS UROSELECTIFS DE L'ADRENO-RECEPTEUR <1?
    申请人:RANBAXY LAB LTD
    公开号:WO2003084928A1
    公开(公告)日:2003-10-16
    Novel α,ω-dicarboximide derivatives which selectively inhibit binding to the α-1A adrenergic receptor, a receptor which has been shown to be important in the treatment of benign prostatic hyperplasia. The compounds of the present invention are potentially useful in the treatment of benign prostatic hyperplasia.
    新型α, ω-二羧酰亚胺生物,可选择性地抑制与α-1A肾上腺素受体的结合,该受体已被证明在良性前列腺增生的治疗中很重要。本发明的化合物有望用于治疗良性前列腺增生。
  • ARYLPIPERAZINE DERIVATIVES AS ADRENERGIC RECEPTOR ANTAGONISTS
    申请人:Salman Mohammad
    公开号:US20090312344A1
    公开(公告)日:2009-12-17
    The present invention relates to α 1 , and/or α 1d adrenergic receptor antagonists, which can function as α 1a and/or α 1d adrenergic receptor antagonist and can be used for the treatment of a disease or disorder mediated through α 1a and/or an adrenergic receptor. Compounds disclosed herein can be used for the treatment of benign prostatic hyperplasia (BPH) and the related symptoms thereof. Further, compounds disclosed herein can be used for the treatment of lower urinary tract symptoms associated with or without BPH. Also provided are processes for preparing such compounds, pharmaceutical compositions thereof, and the methods of treating BPH or related symptoms thereof.
    本发明涉及α1和/或α1肾上腺素受体拮抗剂,其可以作为α1a和/或α1d肾上腺素受体拮抗剂,可用于治疗通过α1a和/或肾上腺素受体介导的疾病或紊乱。本文所披露的化合物可用于治疗良性前列腺增生症(BPH)及其相关症状。此外,本文所披露的化合物可用于治疗与或不伴随BPH的下尿路症状。还提供制备此类化合物的方法,其制药组合物以及治疗BPH或其相关症状的方法。
  • Alpha, omega-dicarboximide derivatives as useful uro-selective a1a adrenoceptor blockers
    申请人:Salman Mohammad
    公开号:US20050228180A1
    公开(公告)日:2005-10-13
    Novel α,β-dicarboximide derivatives which selectively inhibit binding to the α- ,1A? adrenergic receptor, a receptor which has been shown to be important in the treatment of benign prostatic hyperplasia. The compounds of the present invention are potentially useful in the treatment of benign prostatic hyperplasia.
    新型α,β-二甲酰亚胺生物可选择性地抑制与α-,1A? 1A?肾上腺素能受体的结合,该受体已被证明在治疗良性前列腺增生症中具有重要作用。本发明的化合物可用于治疗良性前列腺增生症。
  • WO2006/51374
    申请人:——
    公开号:——
    公开(公告)日:——
  • ALPHA, OMEGA-DICARBOXIMIDE DERIVATIVES AS USEFUL URO-SELECTIVE A1A ADRENOCEPTOR BLOCKERS
    申请人:RANBAXY LABORATORIES, LTD.
    公开号:EP1495000A1
    公开(公告)日:2005-01-12
查看更多